erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
"the big unanswered question is concerns over safety in pregnancy," she says. cgrp levels are lower than normal in pregnant women who have.